Clinical Trial Update: CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CART19 therapy for B-cell hematologic malignancies including various lymphomas and leukemias that are refractory or resistant to chemot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Hematopoietic Lymphoid Cancer
• Mantle Cell Lymphoma

Drugs mentioned

• CART19 (CD19-directed chimeric antigen receptor T cells)

Snippet

Sponsor: University of Pennsylvania | Conditions: Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Status: COMPLETED | Results posted: 2017-02-28